Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Long-term cohort studies

Topic: Risk, prevention and care in population studies

Plain-language summary

Importance Advanced glycation end products (AGEs) and their receptor (RAGE) are implicated in the pathophysiological processes of dementia and potentially underlie the association of diabetes with neurodegeneration. However, longitudinal studies examining this association are lacking. Objective To determine whether markers of the AGE-RAGE system are associated with prevalent and incident dementia and with cognition.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 1,021 participants. In the Rotterdam Study, plasma markers of the advanced glycation end product and receptor system were measured and related to prevalent and incident dementia and cognition. Reported effect size: 56.2%; 55.2%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chen, J., Mooldijk, S. S., Licher, S., Waqas, K., Ikram, M. K., Uitterlinden, A. G., et al. (2021). Assessment of Advanced Glycation End Products and Receptors and the Risk of Dementia. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2020.33012

Vancouver

Chen J, Mooldijk SS, Licher S, Waqas K, Ikram MK, Uitterlinden AG, et al. Assessment of Advanced Glycation End Products and Receptors and the Risk of Dementia. JAMA network open. 2021. doi:10.1001/jamanetworkopen.2020.33012. PMID: 33416887.

BibTeX

@article{chen2021-33416887,
  author  = {Chen, J. and Mooldijk, S. S. and Licher, S. and Waqas, K. and Ikram, M. K. and Uitterlinden, A. G. and Zillikens, M. C. and Ikram, M. A.},
  title   = {{Assessment of Advanced Glycation End Products and Receptors and the Risk of Dementia}},
  journal = {JAMA network open},
  year    = {2021},
  doi     = {10.1001/jamanetworkopen.2020.33012},
  pmid    = {33416887},
  url     = {https://doi.org/10.1001/jamanetworkopen.2020.33012}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In the Rotterdam Study, plasma markers of the advanced glycation end product and receptor system were measured and related to prevalent and incident dementia and cognition. It examines possible biological markers and does not test any treatment, cure, or prevention.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 3 / 4 1,021 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 66 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 9.4 citations a year over 7 year(s) since 2021
Impact for its field and year 3 / 6 Cited 6.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author M. Arfan Ikram: h-index 167 (OpenAlex, whole career)
Institution's track record 1 / 3 Erasmus MC: institution h-index 1,321 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33416887)
Free to read 2 / 2 Free to read
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →